SymbioCellTech has developed a proprietary therapy that has shown long-term glucose control with reduced or no need for insulin injections and toxic antirejection drugs in animal models of Type 1 Diabetes. The therapy provides protection from autoimmune attacks that destroy insulin-producing cells and offers an endogenous and physiologic source of insulin. The company's stem cell-based technology achieves glucose control identical to that of a normal healthy individual and can be administered in a simple out-patient procedure. SCT has completed pre-clinical trials and is preparing for FDA submission and approval to begin clinical trials treating humans suffering from Type-1 Diabetes. Canine clinical trials have been approved, and the outcomes are outstanding.